Vera Therapeutics, Inc. Financing Cash Flow
Vera Therapeutics, Inc. (VERA) reported Financing Cash Flow of $5.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10
- Vera Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.92M, a 90.54% decline year-over-year.
- Vera Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $3.94M, a 157.14% increase year-over-year.
- Vera Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $286.28M, a 12.17% decline year-over-year.
- Vera Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $797.00K, a 7.85% increase year-over-year.
- Vera Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $308.90M, a 49.08% decline from fiscal 2024.
- Vera Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $606.67M, a 354.30% increase from fiscal 2023.
- Vera Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $133.54M, a 31.01% increase from fiscal 2022.
- Vera Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $101.93M, a 89.18% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $5.86M 10-Q · filed 2026-08-10 | $292.14M derived: sum of 3 quarters · filed 2026-08-10 | $292.94M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $3.94M 10-Q · filed 2026-05-07 | $290.22M derived: sum of 2 quarters · filed 2026-05-07 | $291.02M derived: sum of 3 quarters · filed 2026-05-07 | $311.31M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $286.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $287.08M derived: sum of 2 quarters · filed 2026-02-26 | $307.36M derived: sum of 3 quarters · filed 2026-08-10 | $308.90M 10-K · filed 2026-02-26 |
| 2025-09-30 | $797.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $21.08M derived: sum of 2 quarters · filed 2026-08-10 | $22.61M 10-Q · filed 2025-11-05 | $348.57M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $20.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $21.82M 10-Q · filed 2026-08-10 | $347.77M derived: sum of 3 quarters · filed 2026-08-10 | $348.51M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.53M 10-Q · filed 2026-05-07 | $327.49M derived: sum of 2 quarters · filed 2026-05-07 | $328.23M derived: sum of 3 quarters · filed 2026-05-07 | $331.67M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $325.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $326.69M derived: sum of 2 quarters · filed 2026-02-26 | $330.13M derived: sum of 3 quarters · filed 2026-02-26 | $606.67M 10-K · filed 2026-02-26 |
| 2024-09-30 | $739.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.18M derived: sum of 2 quarters · filed 2025-11-05 | $280.72M 10-Q · filed 2025-11-05 | $305.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $279.98M 10-Q · filed 2025-08-05 | $304.81M derived: sum of 3 quarters · filed 2026-02-26 | $305.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $276.54M 10-Q · filed 2025-05-07 | $301.37M derived: sum of 2 quarters · filed 2026-02-26 | $301.67M derived: sum of 3 quarters · filed 2026-02-26 | $302.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $24.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.13M derived: sum of 2 quarters · filed 2026-02-26 | $25.56M derived: sum of 3 quarters · filed 2026-02-26 | $133.54M 10-K · filed 2026-02-26 |
| 2023-09-30 | $297.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $729.00K derived: sum of 2 quarters · filed 2024-11-07 | $108.71M 10-Q · filed 2024-11-07 | $129.42M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $432.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $108.42M 10-Q · filed 2024-08-08 | $129.13M derived: sum of 3 quarters · filed 2024-08-08 | $130.03M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $107.98M 10-Q · filed 2024-05-10 | $128.69M derived: sum of 2 quarters · filed 2024-05-10 | $129.60M derived: sum of 3 quarters · filed 2024-05-10 | $129.65M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $20.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $21.62M derived: sum of 2 quarters · filed 2024-03-27 | $21.66M derived: sum of 3 quarters · filed 2024-03-27 | $101.93M 10-K · filed 2024-03-27 |
| 2022-09-30 | $908.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $956.00K derived: sum of 2 quarters · filed 2023-11-09 | $81.22M 10-Q · filed 2023-11-09 | $86.14M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $80.32M 10-Q · filed 2023-08-10 | $85.24M derived: sum of 3 quarters · filed 2023-08-10 | $85.24M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $80.27M 10-Q · filed 2023-05-11 | $85.19M derived: sum of 2 quarters · filed 2023-05-11 | $85.19M derived: sum of 3 quarters · filed 2023-05-11 | $134.18M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $4.92M derived: sum of 2 quarters · filed 2023-03-28 | $53.91M derived: sum of 3 quarters · filed 2023-03-28 | $53.88M 10-K · filed 2023-03-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $48.99M derived: sum of 2 quarters · filed 2022-11-09 | $48.96M 10-Q · filed 2022-11-09 | $128.76M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $48.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $48.96M 10-Q · filed 2022-08-10 | $128.76M derived: sum of 3 quarters · filed 2022-08-10 | $128.67M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$28.00K 10-Q · filed 2022-05-16 | $79.77M derived: sum of 2 quarters · filed 2022-05-16 | $79.68M derived: sum of 3 quarters · filed 2022-05-16 | $80.30M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $79.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $79.71M derived: sum of 2 quarters · filed 2022-03-28 | $80.32M derived: sum of 3 quarters · filed 2022-03-28 | $85.29M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $522.00K derived: sum of 2 quarters · filed 2021-11-10 | $5.49M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $616.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $5.58M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $4.97M 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |